Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs
NCT06291987Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Sep 2024
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivosidenib and ruxolitinib in myeloproliferative neoplasms (MPN) (3 arms), sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Sep 2024; status: recruiting.
02
Drugs
ivosidenibruxolitinib
03
Conditions
myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT06291987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291987.